Francesca Bergamo
Universidade Estadual do Piauí(BR)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Genetic factors in colorectal cancer, Gastric Cancer Management and Outcomes, Cancer Genomics and Diagnostics
Most-Cited Works
- → Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial(2016)993 cited
- → Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan(2018)399 cited
- → Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial(2022)251 cited
- → Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial(2022)242 cited
- → Clinical pattern and associations of oxaliplatin acute neurotoxicity(2012)219 cited
- → Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life(2016)185 cited
- → FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer(2013)185 cited
- → Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial(2020)176 cited
- → BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection(2015)169 cited
- → HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer(2019)165 cited